• Francesca Orzan, Maria Rosa Terreni, Mauro Longoni, Nicola Boari, Pietro Mortini, Claudio Doglioni, and Paola Riva.
• Department of Biology and Genetics, Medical Faculty, University of Milan, 20133 Milano, Italy.
• Oncol. Rep. 2007 Jul 1; 18 (1): 249-52.

AbstractChordomas are rare neoplasms arising along the axial skeleton. Up to now, the most suitable therapeutic approach is based on a combination of surgical excision and radiotherapy. Chemotherapy in not applied due to its reported low efficacy. Recently, evidence on the efficacy of Imatinib mesylate in two patients has been reported. We analyzed 14 chordoma samples for the expression of the Imatinib mesylate targets by means of RT-PCR and immunohistochemistry and found that PDGFR alpha and PDGFR beta are in some cases expressed in neoplastic cells, while the stromal counterpart of the same tumor shows the above receptors. Findings on the PDGFA/PDGFB expression suggest a receptor-activated status. Our study provides new insights into the specific localization of Imatinib mesylate targets in skull base chordomas that could be taken into account for the setting up of a pharmacological treatment for this tumor.

41 keywords...

hide…